• Erastin as a Ferroptosis Inducer: Optimizing Ferroptosis Res

  2026-05-17

  Erastin, a precision ferroptosis inducer from APExBIO, empowers researchers to dissect non-apoptotic cell death in RAS/BRAF-mutant tumor models with excellent selectivity. This guide delivers actionable workflows, troubleshooting strategies, and evidence-backed insights for maximizing the impact of Erastin in cancer biology and oxidative stress research.

• Amphotericin B in Synergistic Antifungal Research: Mechanist

  2026-05-16

  Explore the mechanistic depth and advanced applications of Amphotericin B, a polyene antifungal antibiotic, in fungal infection research. This article uniquely analyzes synergy strategies and practical assay decisions, offering new perspectives beyond conventional reviews.

• GMDS Drives Fucosylation and Tumor Progression in MYCN-Ampli

  2026-05-15

  This study reveals that GDP-mannose 4,6-dehydratase (GMDS) is a critical enzyme for core fucosylation and tumorigenesis in MYCN-amplified neuroblastoma. By linking high GMDS activity to poor prognosis and identifying de novo GDP-fucose biosynthesis as a metabolic vulnerability, the research provides new insight into potential therapeutic targets for aggressive pediatric cancer.

• P2RX1-Mediated Apoptosis Mechanisms in Ph+ ALL: Insights & I

  2026-05-15

  Li et al. (2025) reveal that P2RX1 overexpression sensitizes Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) cells to mitochondrial apoptosis by disrupting calcium homeostasis and suppressing PI3K/Akt signaling. These findings highlight P2RX1 as a promising therapeutic target and illuminate mechanistic pathways relevant for apoptosis detection and translational research.

• Targeting CYP2B6 in Glioblastoma: ATF5 Peptide Downregulatio

  2026-05-14

  This article reviews the recent discovery that a cell-penetrating dominant-negative ATF5 peptide can downregulate CYP2B6 expression in glioblastoma cells, revealing a novel regulatory axis for modulating drug metabolism in brain tumors. The findings offer mechanistic insight for precision dosing strategies and highlight both technical advances and translational limitations.

• Targeting FABP4: BMS 309403 at the Forefront of Atherosclero

  2026-05-14

  This thought-leadership article presents a strategic and mechanistic roadmap for translational researchers leveraging BMS 309403, a potent FABP4 inhibitor, to interrogate and modulate the CaN/FoxO1/FABP4 pathway in atherosclerosis and metabolic disease models. Drawing on recent high-impact studies, it reviews molecular mechanisms, experimental best practices, and the translational significance of FABP4 modulation, with actionable protocol guidance and a vision for future research impact.

• Hyperthermia and Cisplatin Co-Therapy Drives Caspase-8 Apopt

  2026-05-13

  This article examines recent evidence that combining hyperthermia with cisplatin enhances cancer cell death by promoting caspase-8 accumulation and activation, thereby triggering both apoptosis and pyroptosis. The study uncovers a novel ubiquitination-dependent regulatory mechanism, with implications for optimizing programmed cell death research and caspase activity measurement approaches.

• Magneto-Piezoelectric Scaffolds Activate JAK2-STAT3 for Bone

  2026-05-13

  This study introduces a multifunctional scaffold incorporating magneto-piezoelectric nanoparticles to disrupt bacterial biofilms and stimulate oxidative phosphorylation in Icam1+ macrophages, promoting regeneration in infectious bone defects. Activation of the JAK2-STAT3 pathway is central to the scaffold’s mechanism, offering translational potential for immunoregenerative strategies in complex tissue repair.

• Imipramine in Research: Protocols for Autophagy and Apoptosi

  2026-05-12

  Imipramine from APExBIO is transforming its role beyond classic antidepressant use, offering unique advantages in autophagy and apoptosis research. This article delivers protocol-driven workflows, troubleshooting, and actionable insights for leveraging Imipramine in glioma, leukemia, and neuroprotection studies.

• Scenario-Driven Insights: KPT-330 (Selinexor), Selective CRM

  2026-05-12

  This article delivers actionable, scenario-based guidance for using KPT-330 (Selinexor), selective CRM1 inhibitor (SKU B1464), in advanced cancer research workflows. Drawing on peer-reviewed literature and validated protocols, it addresses key challenges in apoptosis, cell cycle analysis, and xenograft studies, enabling reproducible and insightful results for biomedical scientists.

• GKT137831: Precision Redox Modulation in Translational Scien

  2026-05-11

  This article explores the mechanistic and strategic role of GKT137831, a dual NADPH oxidase Nox1/Nox4 inhibitor, in advancing translational research on oxidative stress. By integrating recent discoveries in ferroptosis, vascular remodeling, fibrosis, and atherosclerosis, we provide actionable guidance for researchers and highlight novel experimental opportunities.

• Tetraethylammonium Chloride: Mechanisms & Applications in K+

  2026-05-11

  Tetraethylammonium chloride (TEAC) is a high-purity potassium channel inhibitor widely used in vascular and electrophysiological studies. Its dual-site blocking action enables precise mapping of ion conduction pathways and assessment of channel mutants. TEAC’s clinical and experimental uses are bounded by specificity and solubility constraints.

• GPR68-ATF4 Axis Controls Ferroptosis Sensitivity in Glioblas

  2026-05-10

  Williams et al. (2024) identify the GPR68-ATF4 signaling pathway as a key pro-survival mechanism in glioblastoma, driven by acidic tumor microenvironments. Their findings show that targeted inhibition of GPR68 triggers ATF4-mediated ferroptosis, offering a promising direction for selective glioblastoma cell death strategies.

• Mubritinib (TAK 165): Precision Inhibition for AML & Virolog

  2026-05-09

  Mubritinib (TAK 165) is redefining targeted research by bridging mitochondrial complex I inhibition with selective cytotoxicity in AML, PEL, and emerging antiviral applications. APExBIO delivers this compound with robust protocols and unparalleled selectivity, making it an indispensable tool for advanced cancer biology and viral pathogen studies.

• WP1066, JAK2/STAT3 Inhibitor: Protocols and Advanced Applica

  2026-05-09

  WP1066, a cell-permeable JAK2/STAT3 inhibitor from APExBIO, empowers precision oncology and regenerative research with its robust pathway blockade and translational flexibility. This guide covers best-practice workflows, troubleshooting, and applied insights, bridging advanced cancer models and innovative tissue repair strategies.

408 records 15/28 page Previous Next First page 上5页 1112131415 下5页 Last page